ARDS is a syndrome, yet we treat it as though it was a single clinical disease. There has been success in improving the process of care for patients with ARDS, but no real progress on address the underlying process. For successful therapies to influence the disease process, we need to be able to distinguish the mechanisms active in individual patients and so that we can design and test interventions targeting the specific ...more »
Many lung diseases (IPF, COPD) are characterized by marked heterogeneity at the tissue level. Unfortunately, most of the tools we currently employ to understand lung disease are unable to elucidate the mechanisms that result in regional heterogeneity. Clinical studies and animal models, while invaluable, generally assume that all lung tissue is similarly affected based on the presence or absence of diagnostic criteria ...more »
What are the regional variations in cellular and molecular characteristics (from epigenetics to microbiome) in the lung, and what controls these variations?
What defines the heterogeneity of normal pulmonary vascular endothelial cells?